Facing entry of follow-up drugs, Tamiflu to be launched in a new formation
‘Tamiflu,’ an antiviral drug which soon will face the entry of follow-up drugs due to the expiration of its substance patent, has attracted attention of the industry with different volume types.
According to the Ministry of Food and Drug Safety on the 14th, Roche Korea has recently acquired appr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
